The AIM-listed firm, which commercialises intellectual property, said as part of the partnership Exscientia was entitled to become a GT Apeiron shareholder and receive milestone payments and royalties based on the clinical and commercial success of its drug discovery programmes.
GT Apeiron was launched by GT Healthcare Capital Partners (GTH), a life science-focused private equity partnership, with US$27mln of financial backing.
GTH is also an investor in Exscientia having participated in a US$26mln funding round previously.
Professor Andrew Hopkins, Exscientia's chief executive, said medicines generated by the collaboration would focus on areas of “significant unmet need with global potential”.
"This is an exciting time for pharmaceutical research, with innovative approaches to drug discovery as well as the development of new commercial markets. Both are strongly evident in China, already the second largest national pharmaceutical market in the world, where we are delighted to join our expertise and technology with GT Apeiron to initiate our first discovery opportunity in the country”, the CEO added.
Frontier holds a 3.32% stake in Exscientia.
The shares were up 0.6% at 79p in early deals.
--Adds share price--